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ScienceDirectThe recent interest in epigenetics within mental health
research, from a developmental perspective, stems from the
potential of DNA methylation to index both exposure to
adversity and vulnerability for mental health problems.
Genome-wide technology has facilitated epigenome-wide
association studies (EWAS), permitting ‘hypothesis-free’
examinations in relation to adversity and/or mental health
problems. In EWAS, rather than focusing on a priori established
candidate genes, the genome is screened for DNA methylation,
thereby enabling a more comprehensive representation of
variation associated with complex disease. Despite their
‘hypothesis-free’ label, however, results of EWAS are in fact
conditional on several a priori hypotheses, dictated by the
design of EWAS platforms as well as assumptions regarding
the relevance of the biological tissue for mental health
phenotypes. In this short report, we review three hidden
hypotheses — and provide recommendations — that
combined will be useful in designing and interpreting EWAS
projects.
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Understanding the biological mechanisms by which early
psychosocial adversity associates with long-term mental
health problems may have the potential to facilitate the
development of effective screening, intervention strate-
gies and health policy decisions [1]. Recent research has
focused on the degree to which adversity disrupt gene
regulation through epigenetic processes, thereby provid-
ing a mechanism by which the environment can have
lasting effects on measurable mental health phenotypes
[2]. High profile studies suggest that epigenetic changes
associated with early adversities [3,4] and even lifestylewww.sciencedirect.com choices [5] can be observed across the life span, and that
these long-term epigenetic modifications are associated
with risk for a range of health outcomes [6]. These studies
have generally focused on DNA methylation (DNAm) for
two reasons: it is currently the best understood epigenetic
mechanism and array-based technologies are readily
available, which provides coverage of hundreds of thou-
sands of methylation sites across the genome [7]. This
combination of basic science and genome-wide technol-
ogy has facilitated numerous epigenome-wide association
studies (EWAS), permitting ‘hypothesis-free’ examina-
tions in relation to adversity and/or mental health
problems.
The logic underlying EWAS is comparable to genome-
wide association studies (GWAS [8]). Rather than focus-
ing on DNAm in proximity to candidate genes, the
genome is screened for DNAm, thus enabling a more
comprehensive representation of variation associated
with complex disease. As with GWAS (e.g. [9,10]),
despite their ‘hypothesis-free’ label, results of EWAS
are in fact conditional on several a priori hypotheses,
dictated by the design of EWAS platforms as well as
assumptions regarding the relevance of the biological
tissue for the mental health phenotypes under investiga-
tion. In this short report, we review three hidden hypoth-
eses (see Figure 1) — and provide recommendations —
that combined will be useful in designing and interpret-
ing EWAS projects.
Hidden hypothesis 1: EWAS coverage is
sufficient for complex psychiatric problems
Array-based platforms have become widespread in psy-
chology research, largely due to their ease of use, rela-
tively high through-put, and well standardised and vali-
dated pipelines for processing, quality control, and
analysis techniques. In particular, the Illumina 450k
and EPIC arrays feature 480 000–850 000 probes targeting
nearly 99% of RefSeq genes, as well as a range of other
genomic categories, such as CpG islands, shores and
shelves, miRNA promoters and enhancers, where DNAm
can be influenced by and/or impact transcription in distal
genomic regions [11]. Compared with the Ilumina 450k,
the newer Illumina EPIC 850k array provides much
greater coverage of ENCODE and FANTOM5 enhan-
cers [12], and shows higher genetic influence underly-
ing DNAm probes [13]. Nevertheless, these microarrays
are limited in the number of sites they can assess, and thus
lack true genome-wide measurements [14].Current Opinion in Psychology 2019, 27:13–17
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Hidden hypotheses in epigenome-wide approaches. Note: (1) = Hypothesis 1: EWAS coverage is sufficient for complex psychiatric problems;
(2) = Hypothesis 2: peripheral tissue is meaningful for mental health problem(s); and (3) = Hypothesis 3: biology can be meaningful to phenotype of
interest.Furthermore, during the design process of the 450k and
EPIC arrays, CpG sites were chosen as potentially bio-
logically informative based on consultation with a consor-
tium of DNA methylation experts [15]. Whilst the cover-
age of genes and CpG islands on these microarrays are
comprehensive, it does not represent a complete picture
of methylated cytosines across the genome. Selection
was, in part, based on data from a number of phenotypes
(some medical in nature such as cancer), and thus is not
specifically targeted to brain-based, stress-related com-
plex mental health phenotypes. This is an important
point: if a sizeable proportion of the CpG sites tested
are not relevant to the phenotype of interest, the likeli-
hood of detecting relevant results is reduced.
Hidden hypothesis 2: peripheral tissue is
meaningful for mental health problem(s)
The second hidden hypothesis relates to the tissue that is
used to quantify DNAm. The majority of mental health
research is based on DNAm profiles obtained from
peripheral tissues from living persons, such as blood
and saliva. When investigating outcomes such as conductCurrent Opinion in Psychology 2019, 27:13–17 disorder or depression, however, the brain is often the
main tissue of interest when it comes to mechanistic
interpretations of results [16]. To this end, research
suggests that the correspondence of methylation profiles
from blood and saliva to the brain is in fact quite limited,
but can be higher with cross-tissue genetic influence
[13,17]. This presents a critical disadvantage if the inves-
tigator would like to use the peripheral tissue as a surro-
gate of the central nervous system (CNS; the brain).
One promising avenue is to establish DNAm as a bio-
marker for mental illness. A biomarker does not have to
be mechanistic (i.e. CNS surrogate). Indeed, blood-based
biomarkers have been used for diagnostics, predictive
risk, disease monitoring and/or treatment response in
cancer, cardiovascular and infectious disease [18,19].
However, even within a biomarker framework, the
assumption is often that distinct peripheral tissues are
interchangeable and equally suited for biomarker detec-
tion, when in fact it is highly probable that peripheral
tissues themselves correspond differently to environmen-
tal adversity and/or disease state [14]. For instance,www.sciencedirect.com
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be more detected in blood than saliva, as blood is more
central to inflammatory processes related to stress and
disease [16].
Hidden hypothesis 3: biological relevance for
the phenotype of interest
The last hypothesis relates to the assumption that biology
can be informative to the phenotype itself. Focal pheno-
types (e.g. oppositional defiant disorder, anxiety) in men-
tal health research are often complex and multiply deter-
mined [20]. The lack of established robust biomarkers for
mental health problems (e.g. [19]) may suggest that some
of these traits might not strongly associate with detectable
biological processes. Furthermore, effect size associations
in EWASes are often very small suggesting that — while
significant — distinguishing the importance of DNAm in
the aetiology of the mental health phenotype may prove
difficult [21]. Perhaps unsurprisingly then, most EWAS
in mental health include some form of gene ontology
analysis, which queries the role of larger biological sys-
tems based on existing databases [22]. These analyses
result in general statements such as ‘neurodevelopment’
or the ‘immune system’ being involved in the aetiology of
a given phenotype. Whether these broad categories play
indeed a substantial role in the aetiology of the mental
health problem is often hard to determine given the post
hoc nature of the interpretation. Relatedly, many
EWASes have tried to infer downstream effects of
observed variation in DNAm such as differences in gene
expression. Many of these studies find very little in terms
of functional relationships, but a small number do report
downstream biological associations (e.g. [21]). In gen-
eral, it has proven difficult to pinpoint EWAS-related
biological relevance of observed DNAm changes, even
if they are in genes which seem ‘plausible’ based on
reported functionality and previous literature.
Recommendation for hidden hypothesis 1:
EWAS coverage
An alternative to using arrays with limited coverage is to
use next-generation sequencing-based approaches to
interrogate the whole methylome [21]. However, these
methodologies are high in cost and time intensive.
Despite the limitations described above, pragmatic and
strategic study design can maximise utility and interpre-
tation of results of the Illumina 450k and EPIC arrays. For
example, for researchers interested in targeting CpGs
likely to associate with ‘brain-based’ mental illnesses,
an a priori set of CpGs (e.g. a ‘systems approach’) could
be isolated from the array data, which could still span
thousands of loci. The suggestion is to prioritize CpGs
within biological systems that are known to associate with
variation in post-mortem brain samples [23] or even
structural or functioning brain imaging [24] if this is of
primary interest to the investigator.www.sciencedirect.com The second recommendation for optimising the use of
EWAS CpGs is to target those probes with underlying
genetic influence — methylation quantitative trait loci
(mQTLs). This approach may have the advantage that
cross-tissue concordance (e.g. blood, saliva, post-mortem
brain) appears higher for CpGs that show cross-tissue
genetic influence [13]. Another advantage of mQTLs is
that CpGs under considerable genetic influence are less
affected by confounds [11,13,25]. However, while
mQTLs are a worthwhile approach, it is a relatively
new area and at present, there is a small proportion of
methylation sites with consistently reported mQTLs
[11,13]. Furthermore, large-scale and detailed informa-
tion on tissue-specific mQTLs is still sparse.
Recommendation for hidden hypothesis 2:
peripheral tissue and phenotype
One strategy to maximise the interpretability of EWAS
projects is to examine DNAm as a biomarker for mental
health problems that have mechanistic underpinning in
tissues other than the brain, such as blood. A wide-range
of psychiatric disorders have been associated with
immune function as measured by peripheral inflamma-
tion [26]. Furthermore, there is good evidence from
animal studies, and increasing evidence in humans, that
peripheral inflammatory markers can affect brain areas
implicated in certain psychiatric disorders [27]. Conse-
quently, adversity-related immune processes and DNAm
may be well measured in blood samples (see [28]). For
biomarkers to be useful, they must be cost effective,
drawn from accessible tissue and predictive of future risk
[29]. Biomarkers for brain-based disorders (e.g. depres-
sion) have proven more difficult to establish [19]. Liu et al.
[30] performed an EWAS on blood tissues across 13 pop-
ulation-based cohorts and reported that a composite bio-
marker (consisting of 144 CpGs) discriminated drinkers
from non-drinkers. It was thus suggested that a blood-
based DNAm diagnostic test could be developed. It is
important to note, however, that in addition to methodo-
logical considerations [31], the Liu et al. study was cross-
sectional, thus it may prove difficult to use this specific
biomarker as a predictor of future alcohol use, as the
variation in DNAm may be the result of chronic drinking
(i.e. reverse causality [32]). Importantly, large-scale meta-
analyses based on new and growing consortia (e.g. PACE
[33]) are beginning to report consistent epigenetic
effects on traits such as schizophrenia or smoking behav-
iour (e.g. [34,35]) which suggests that we may begin to be
able to utilise this information to further optimize DNAm
biomarker approaches.
Recommendation for hidden hypothesis 3:
phenotype and biology
Several suggestions have been put forward to address the
complex nature of the biology that may underlie mental
health problems. Most notably, the Research Domain
Criteria (RDoC) initiative has proposed alternativeCurrent Opinion in Psychology 2019, 27:13–17
16 Geneticsapproaches to study mental illness by integrating many
different levels of information including genetics, neu-
rocircuits and behaviour [36]. Methylation-based research
can be integrated into an RDoC perspective. Here,
researchers could employ a two-stage analysis, first inves-
tigating epigenetic effects on intermediate dimensions of
mental health and then, using the results as biomarkers to
query the more complex phenotypes. For, example, if
externalising difficulties (e.g. ADHD, aggression) are the
focal phenotype, rather than performing an EWAS
directly on the disorder(s), the researchers could instead,
as the first step, perform an EWAS on brain imaging
endophenotypes of the externalising phenotype (e.g.
[24]). In the second step, the results of the EWAS could
be used to create poly-epigenetic genetic biomarker score
(e.g. [28]) to be (potentially) associated with the disor-
der. This type of two stage of EWAS may examine the
epigenetic changes associated with antecedents of diag-
nosable mental health conditions, which would be could
be more useful as a risk biomarker than a biomarker of the
actual diagnosis.
Conclusion
The recent interest in epigenetics, from a developmental
perspective, stems from the potential of DNA methyla-
tion to index both exposure to adversity and vulnerability
for mental health problems [2]. To this end, there has
been substantial activity in examining EWASes of adver-
sity-related disorders, such as conduct disorder [37] and
psychosis [38]. Of interest, from these EWAS, DNAm in
genes that underlie stress response, neurotransmitter
activity and immune regulation have been identified.
These preliminary findings may provide a useful frame-
work for more in-depth investigations — potentially as
CNS surrogates or biomarkers — of the biological patho-
genesis of a mental health problem. However, we argue
that understanding hidden hypotheses within the EWAS
is an important first step in interpreting the results in
relation to mental health phenotypes.
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